Figure 2.

Alleviation of mechanical allodynia and downregulation of DRG Epac1, NR2B and Piezo2 expression by intrathecal injection of Epac1-ASODN in mice with BCP. Three groups of tumor-bearing mice (n=8/group) received intrathecal saline (5 µl), Epac1-ASODN (10 µg/5 µl) and Epac1-MMODN (10 µg/5 µl) once a day for three consecutive days (from day 14 to 16 after operation). (A) PWMT was measured on day 14 before administration and days 17, 19 and 21 post-operation. (B and C) Expression level of Epac1, p-NR2B and Piezo2 of the ipsilateral lumbar DRG L2-L5 segments were detected with western blotting (n=3/group) or reverse transcription-quantitative PCR (n=3/group) at the corresponding time point. Data represents means ± SD. ^#P<0.05 vs. day 14 before administration; *P<0.05 vs. vehicle group at each time point. ASODN, antisense oligodeoxynucleotides; MMODN, mismatch oligodeoxynucleotides; BCP, bone cancer pain; DRG, dorsal root ganglion; PWMT, paw withdrawal mechanical threshold.